Feed VRTX
VR

Vertex Pharmaceuticals VRTX · NASDAQ

$501.95 +0.44% (+$2.21)

Market cap
$126.7B
Enterprise value
$122.5B
P/E
28.8x
Forward P/E
28.0x
PEG
-
P/S
10.0x
P/FCF
33.4x
EV/EBITDA
22.5x
ROIC
17.3%
Bruto marža
86.0%
Neto marža
34.9%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-0.8x
Beta
0.32
Free float
99.8%

O podjetju

Vertex Pharmaceuticals (VRTX) is a leading biopharmaceutical company specializing in the development of drugs for the treatment of rare and severe diseases. Their primary focus is on the development of innovative therapies for patients with cystic fibrosis, a genetic disorder affecting the respiratory and digestive systems. Vertex Pharmaceuticals is at the forefront of gene therapy and molecular-based treatments. Vertex Pharmaceuticals stock is suitable for investors interested in the pharmaceutical sector and investments in the treatment of rare diseases. Add Vertex Pharmaceuticals stock to your watchlist on Bulios and be the first to receive updates on new medical breakthroughs and the development of therapies from this prominent company.

Sector

Healthcare

Industry

Biotechnology

CEO

Reshma Kewalramani

Employees

6,400

Headquarters

Boston

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.